Sir Kenneth Murray-Ken to his friends-was held in high esteem and affection by all who knew him. In a remarkable career, which began after he left school at the age of 16 years, he played a prominent part, through his elegant and meticulous research, in the evolution of biotechnology; he trained and inspired generations of students entering this bright new discipline; he developed the means of diagnosing, preventing and treating a feared disease, thereby saving many thousands of lives; he was one of a small coterie that founded the first Europe-based biotechnology company; and he used the profits that this yielded to enrich his university and promote, through the charity that he founded, the careers of promising young scientists. He remained, throughout, modest, unassuming and ever willing to give of his time and knowledge to all who asked.
Drawn to science, Ken joined the Nottingham company of Boots the Chemist (as it was then called) as a laboratory assistant. From Boots he moved to an outstation of the Glaxo pharmaceutical concern in Ulverston in the Lake District, where he was able to indulge his love of hillwalking and climbing. During this time he evidently reasserted his scientific promise, for his supervisor encouraged him in his ambition to improve his prospects by gaining a degree. And so, with the help of a scholarship from Glaxo, he enrolled as a part-time undergraduate in chemistry at the University of Birmingham, and in due time was awarded a first-class honours degree. In his introductory foray into research, while still an undergraduate, he took part in projects of Maurice Stacey FRS, the head of the department, exploring arcane corners of saccharide chemistry (especially an anomalous reaction resulting in the synthesis of isomers of a complex condensation product, mannosyl-d-glucosamine hydrochloride). That led to a pair of reports, published some years later in Nature (1, 2)*.
It was 1956 when Ken took his first step in the direction of biology as a PhD student, although still in the Chemistry Department. His supervisor was the genial Arthur Peacocke (later the Rev. Canon A. R. Peacocke, theologian and prolific writer on science and religion, winner of the Templeton Prize, inter alia), and Ken was set to work on the composition and properties of what is now called chromatin (3) . During this time, as his nephew, Keith, recalls, he supplemented his meagre grant by occasional work as a labourer on building sites. It was during this period also that he met a fellow PhD student, Noreen Parker, a protégée of the noted geneticist, David Catcheside FRS. Ken and Noreen married in 1958, and so began a happy union and close scientific partnership that endured until Noreen's death in 2011. In late 1959 Ken emerged a freshly minted PhD, as did Noreen (figure 1), and took ship for America to begin his independent career in research.
Postdoctoral years: stanford and cambridge
Ken's choice of a laboratory for his postdoctoral work was dictated by his PhD research. J. Murray Luck at Stanford University in California was a biochemist, one of whose interests lay in the histones, the family of basic proteins associated with DNA in eukaryotic cells. Little was then known about the function of these proteins, and not a great deal about their structure. Noreen also found a position at Stanford, and the Murrays' intention was to remain there for a year or a little more. In the event they stayed for five profitable years, enjoying, among other things, climbing in Yosemite (figure 2). Ken was left largely to his own devices, and he set out to purify and characterize the histones from one source, the calf thymus gland (6) . His definitive review in Annual Reviews of Biochemistry (5), encompassing the state of knowledge on the basic proteins of chromatin, appeared in 1965.
The Murrays had returned to England the year before that, he to join the division under Fred Sanger FRS at the Medical Research Council's Laboratory of Molecular Biology in Cambridge, she to the Botany Department of the university. Life with Sanger was once again a happy and enlightening experience, for which Ken remained grateful ever after. He formed lasting friendships, the most important of which was probably with César Milstein (FRS 1975) , who shared the 1984 Nobel Prize in Physiology or Medicine with Georges Köhler for the discovery of monoclonal antibodies. Murray and Milstein published a paper on an * Numbers in this form refer to the bibliography at the end of the text. unsuspected source of errors in amino acid analyses (7) . Although never losing his fascination with histones, Ken took an active interest in the epoch-making DNA sequencing techniques that Sanger was then developing. What he learned during this time was to stand him in good stead years later in the work that made him famous. But the Murrays' stay in Cambridge was not without its vicissitudes, and as the duration of Ken's fellowship drew to a close it became a matter of urgency to find a more durable berth; he therefore applied for a lectureship, and Noreen for a fellowship, at the recently established University of York. Both were successful and they prepared to leave Cambridge. At this point the hand of providence intervened, for shortly before the appointed date the Murrays had a car accident. It was serious enough for Ken to request a short delay in their arrival in York. He would in the interim commute from Cambridge to deliver his lectures. In reply he received the following missive from the University Secretary:
Dear Murray-Postponement is unacceptable. You will be in York by 30 September.
Yours faithfully … Ken related that the first and only time he saw Sanger angry was when he was shown this uningratiating letter. Sanger responded by finding further support for Ken to remain in Cambridge until something more desirable should turn up. Meanwhile, he said, Ken should discharge his lecturing obligations in York and then resign. It was to be another two years before the hoped-for opportunity came. It arrived in the form of a letter from Martin Pollock FRS, founding Professor in the Department of Molecular Biology at the University of Edinburgh, the first such department in Britain. Moreover, the thriving MRC Microbial Genetics Unit, directed by William (Bill) Hayes FRS, was due shortly to move from Hammersmith Hospital in London to Edinburgh, and would accommodate Noreen. All were to be housed in a new building. This was the best possible solution for the Murrays, and a cause for gratitude that the car crash and the churlish secretary at York had combined to deflect them from joining a vestigial department with minimal laboratory facilities and as yet no library.
edinburgh
And so in 1967 Ken took up his position as Senior Lecturer in Molecular Biology in Edinburgh, eventually becoming a reader in 1973, and a professor in 1984. He and Noreen found the university and also the city congenial from the beginning, and remained loyal to both for the rest of their lives. For a time Ken continued to occupy himself with the histones, as he had done in Cambridge, and in 1969 produced a comprehensive study on successive stripping of the different histones from chromatin, and the structural effects on the residual complex (8). But his focus had been shifting to the histone genes and the mechanism of their expression in the cell (9, 17) . He also published, starting from his time in Stanford (4), some of the first observations on postsynthetic modifications of histones in the cell, a topic that was later to acquire huge importance in relation to the control of gene expression and imprinting.
It was nevertheless something quite different that was starting to grip Ken's imagination, probably helped along by the turn that Noreen's research was taking (see the memoir of Noreen Murray in this volume (Gann & Beggs 2014)). Ideas about the production of proteins by gene cloning and expression in bacteria-still regarded by many as akin to science fiction-were taking shape. Moreover, it had become clear that restriction endonucleases, discovered not long before, were the key to success. These enzymes are produced by bacteria as a protection against bacteriophages. In some cases the nuclease is encoded in the bacterial genome; in others it derives from a plasmid, an independently reproducing body in the bacterial cell. The property that makes the restriction nucleases so indispensable to molecular biologists, as much as to the bacterium, is the highly selective nature of the targets on which they act. All restriction nucleases recognize a site in an alien DNA comprising a defined sequence of generally four to six nucleotides, and the enzyme will cut the chain at this point, or in some cases elsewhere in the vicinity. The DNA is broken into pieces (restriction fragments), their number and sizes depending only on how many times the critical short nucleotide sequence appears in the chain. At that time, however, these properties had been only sketchily defined, and none of the enzymes had been isolated.
Noreen, a botanist by training and inclination, had specialized in the genetics of fungi, in particular Neurospora crassa, a bread mould. While still in Cambridge she became dismayed at the disdain of the molecular biologists for the organism she loved, and decided to re-train in something closer to current trends. She consulted her friend Frank Stahl, and they agreed that she would spend her evenings in his laboratory to learn phage genetics. The phage she chose to study, called lambda, is a parasite of the geneticists' favourite bacterium, Escherichia coli, and was to serve as the vector that would carry a piece of DNA containing the foreign gene of choice into the bacterium. Then the bacterium would be cultured, the expressed protein harvested, and the task accomplished.
Ken and Noreen were not of course alone in entertaining this alluring vision, and the ferocious competition that soon erupted was wholly alien to Ken's temperament. The principal tools for the enterprise would be a suitable vector, an appropriate restriction endonuclease and a ligase, an enzyme already available, that joins apposed DNA strands end to end. But the challenges were formidable, a major one being the lack of any preparation of a pure restriction endonuclease. The lambda vector proved an inspired choice. Noreen had made herself a virtuoso in its manipulation, and it had, moreover, several properties that made it peculiarly suited to the purpose. It has a linear genome that assumes a closed circular form when it enters its host bacterium, which can belong to any of several strains of E. coli. It achieves this transformation by bringing into apposition a pair of short single-stranded complementary DNA sequences at its ends. As Ken envisaged it, a restriction nuclease would induce a break in the lambda phage DNA, modified to contain only one cleavage site, and the gene would be inserted into the gap. But that still presupposed knowledge of how and where a given restriction enzyme would cut a long DNA molecule. Ken occupied himself (figure 3) with these and many other related problems for the next few years.
The most felicitous feature of some, although not all, restriction enzymes is that they make staggered cuts in the two strands of a DNA duplex, thereby leaving a single-stranded overlap at the ends of the fragments. These 'cohesive ends' allow a segment of DNA containing a gene of interest, with single-stranded overlaps at its ends that are complementary to those created by the restriction enzyme, to be spliced in. The inserted fragment is then sealed in place covalently by the ligase. Thus the extraneous gene has been slipped into its recipient DNA-one that can function as a vector to carry the ensemble into a bacterium or other suitable cell-and the encoded foreign protein can then be expressed. This simple concept (illustrated in figure 4) evolved into the refined technology that was to transform biomedical and pharmaceutical research and much of diagnostic and therapeutic clinical practice. consummation: the first recombinant dna
It had taken no little time, skill and effort to run a restriction enzyme to earth. The report from Meselson's laboratory at Harvard announcing the isolation of EcoK from a strain of E. coli appeared in 1968, a year after Ken's arrival in Edinburgh, and seemed to come at an opportune moment for the Murrays. In the event it was a poisoned gift. Noreen created lambda phage variants with only a single target site to receive a restriction fragment generated by the enzyme, and Ken began to determine terminal sequences. It presently transpired that all was not as it seemed. EcoK was the first member of the Type I class of restriction nucleases. Although these enzymes recognize a specific target sequence in DNA as expected, they cut the chains of the double helix at many random points. This was a disappointment, and occasioned a considerable loss of time.
The Murrays did not repine. Another leading American group purified a more promising restriction endonuclease from a different E. coli strain. This was EcoRI, and it drove Ken to trawl the E. coli plasmids (for one of these had been the source of EcoRI), and thus EcoRII came to light (10) . The search for restriction enzymes became frenetic, because the greater the choice of sequence elements at which DNA chains could be severed, the greater the chances of isolating an intact (for instance human) gene and of splicing it into a vector. Ken and his small team purified two more restriction enzymes and were approached by Hamilton Smith (awarded the 1978 Nobel Prize in Physiology or Medicine for his work in this area), who had found restriction activity in a strain of the bacterium Haemophilus influenzae. Ken and his colleagues found that the extract sent by Smith contained not one but two enzymes. Smith had given the presumptive enzyme the name HindII, to which Ken now added HindIII. Ken and his group purified both enzymes and determined their cutting sequences (11) . Later another restriction enzyme emerged from Ken's labours. This was Sau3a-a further addition to the molecular biologist's toolbox.
The outcome of this painstaking work inevitably thrust Ken into the turbulent waters of recombinant DNA and genetic engineering. The intoxicating promise that the emerging technology so obviously held attracted leading molecular biologists from around the world. The mounting pressure of competition would have been borne in on Ken when, in 1972, he and Noreen attended a conference at which he announced the discovery of EcoRII and HindIII, giving full details of their recognition sequences and other properties. This meeting was also the occasion on which two workers from the University of California in San Francisco reported on the isolation of EcoRI and HindII, but the characterization was incomplete and they asked Ken to hold up publication of his results until they had completed their own work, so that the two reports could appear together. Ken chivalrously acceded to their wish, and six months later the two papers were submitted for simultaneous publication.
Ken and Noreen learned at this conference that EcoRI was a Type II restriction enzyme, which made staggered breaks in the two DNA strands within its recognition region, therefore leaving the desired single-stranded tails on the severed duplex. This set the Murrays on the path to a recombinant DNA. The first step was to modify the phage genome by eliminating all except one EcoRI target site, at which the enzyme would create a break with 'sticky' ends. This being accomplished, it did not then take Ken long to construct the first recombinant DNA based on the lambda phage. The resulting paper was published some time later, in 1975 (12), followed by two more on the creation of nuclease recognition sites in lambda DNA (13, 14) . The Murrays' route to the expression of protein-encoding genes, by way of the lambda phage cloning vector, came into general use and remained so for some years (N. E. Murray 2006). It secured for the Murrays a place among the architects of the new science.
The wild surmise of a few years before, that bacterial cultures would soon be pro ducing any desired proteins at will, now seemed a reality. Yet there were still difficulties to be confronted. The means were already available, at least in principle, of generating pieces of DNA containing a selected gene, but complementary cohesive ends had to be contrived. The phage vector carrying its burden had not only to invade the bacterium but also to fulfil the need, having entered, to multiply and destroy its host. It remained essential that the vector genome contain only a single restriction site for any restriction enzyme to be deployed. Then there was the constraint on the amount of DNA that the phage head-the globular structure containing the DNA-could accommodate. This placed a strict limit on the permissible size of the inserted material and therefore of the protein that could eventually be expressed. The efforts of many laboratories contributed to the resolution of these problems. Noreen and Ken made good use of the discovery that the lambda phage could dispense with as much as 40% of its genome without detriment to its invasive function. This meant that the space vacated by the endogenous DNA could be filled by an additional length of the foreign DNA. In the period after 1974, the year in which the Murrays published their first reports on the creation of a recombinant DNA, cloning and expression techniques were evolving rapidly, and the 'insertion cloning' devised by the pioneers was being supplanted by other more versatile and efficient procedures. The most important of these innovations was the use of plasmids to carry an inserted gene. Plasmids are abundant in bacteria (and occasionally also appear in other unicellular life forms). Plasmids replicate independently of the host DNA, and their DNA is generally, like that of the lambda phage, a closed circular double helix. The use of plasmids as cloning vehicles circumvents much of the heroic labour that went into the manipulation of phages, and plasmids were used by Ken Murray in his later work (below) on the hepatitis B vaccine. Today all constituents involved in protein expression, if not the whole procedure itself, are bought from biotechnology companies. The pioneering achievements of the Murrays in genetic engineering are discussed in much greater and authoritative depth by Gann & Beggs (2014).
Virus and Vaccine
In the late 1970s Ken Murray took the decision to enter new territory: he would work on something with an explicit medical thrust. In 1978 he and a small group of like-minded individuals formed a plan to set up a commercial enterprise. Among them were leading biologists and enlightened investors, and their vision was to exploit new discoveries judged to hold therapeutic or diagnostic promise. Thus Biogen came into being (figure 5). It was the first biotechnology company based in Europe. Ken proposed viral vaccines as one line of research that could profitably be pursued, and it was hepatitis B that he mainly had in mind. A motivating factor was undoubtedly the sense that hazards and uncertainties inseparable from the classical methods of vaccine development could become a thing of the past. These methods had, to be sure, given the world the poliomyelitis vaccine, among many others, but recombinant DNA technology should now have the capacity to supersede them. Whether Ken was influenced by the recollection of a devastating outbreak of hepatitis B nearly 10 years earlier in the Edinburgh Royal Infirmary is not clear, but the disease and its consequences were in any case often in the news. The infection had struck in the renal unit, apparently spread through dialysis machines contaminated with traces of exchanged blood, and 40 people had been affected. Of these, eleven had died directly from the disease: seven patients, two laboratory technicians and two transplant surgeons. This resulted in 1970 in the temporary closure of the only dedicated transplant unit in Britain. But the Royal Infirmary was by no means the only medical centre touched by hepatitis B: the renal unit at Guy's Hospital in London recorded 69 cases, 32 of them in members of the staff, and was closed; and there were lesser outbreaks in hospitals around the country. The reported deaths underestimate the full impact, for the infection all too commonly leads to liver cancer.
There were at the time two possible routes to a vaccine: antibodies could be raised against either killed or attenuated virus. A virus could be killed chemically or by heat. Attenuation meant passaging the virus several times through animals or through cells in culture until it mutated (so it was hoped) into a harmless form. Both methods had their disadvantages. Isolation of the virus and the succeeding steps were both laborious and dangerous. The killed virus must be free of even the minutest residuum of live particles and yet retain enough of its antigenic potency. Attenuated virus could sometimes revert to the virulent state. The traditional methods assuredly had their successes, most famously the elimination of smallpox and poliomyelitis, but not all viruses responded so well, and vaccination against hepatitis B had achieved only limited results. The only animals susceptible to infection are humans and monkeys. Thus the available hosts and cell lines in which the virus could be propagated were severely restricted. A vaccine made from the killed virus was developed in the USA and approved by the Food and Drug Administration (FDA), but it was expensive and of limited efficacy. Ken judged that the time had come to apply the methods of genetic engineering to the problem. There were now tolerably reliable cloning and expression procedures, and the sequencing of short pieces of DNA and the synthesis of oligonucleotides were both routine. There were still at this time relatively few genetic engineering practitioners, and Ken was one of the leaders. Yet the task was daunting, and compounded at the outset by the requirement-unaccountable as it now seems-that all genetic manipulations involving the construction of genetic hybrids between two species (in this case the virus and the bacterium, E. coli, for the purpose of cloning and expression) had to be performed under conditions of high physical and biological containment. This ruling arose from a wave of concern over the creation of new life forms, and the fear they might leak into the environment and cause mayhem. In 1975, in the wake of a meeting on recombinant DNA (the Asilomar Conference), the containment restrictions on, in essence, all recombinant DNA experiments were promulgated. In particular, the laboratory had to be maintained at negative pressure, so that airborne particles could get in but not out; in addition, the host bacteria had to be genetically enfeebled, so that even if they did escape into the outside world they would not survive. Few universities in any country could boast the necessary facilities, and so Ken was compelled, until the ban was lifted, to travel to the Microbiological Research Establishment at Porton Down on Salisbury Plain to continue his work. He pressed on.
The first inescapable step on the way to a vaccine had been to procure a virus sample from the blood of a seriously ill patient. This was provided by colleagues in the Department of Bacteriology in Edinburgh, and Ken could set out on his first task, a comprehensive analysis of the viral genome to identify possible antigenic targets. The initial plan was to isolate segments of DNA that might contain genes or parts of genes encoding coat proteins-the essential constituents of the outer layer of the virus-splice each into a suitably engineered lambda phage vector, insert that into E. coli, and search for antigenic activity in the polypeptides produced by the bacteria. Ken, in collaboration with his friend Peter Hans Hofschneider and members of his laboratory in Munich, succeeded (15) (as, almost simultaneously, did workers in France and in America) in cloning pieces of the viral DNA. In doing this they departed from Ken's lambda-based procedure, using instead a plasmid as cloning vehicle. Expression in E. coli led to an illuminating result: the product, in some cases, harboured a polypeptide that reacted with an antibody directed against an antigen (HBcAg) in a coat protein of the virus. This was an encouraging pointer to a vaccine.
A collaboration between Ken and his colleague Walter Gilbert and his research group at Harvard led to the next major advance, which eliminated to a large extent the hit-and-miss nature of the foregoing methods. The virus DNA fragments were inserted into the vector at a restriction site within the gene for an enzyme (β-lactamase), easily identified by its nucleotide sequence. Therefore an expressed polypeptide with antigenic activity would emerge fused to a β-lactamase protein sequence. It follows that the β-lactamase gene would be adjacent to or at least very close to the gene specifying the virus antigen. The sizes and terminal sequences of the coat and core (that is, internal) proteins of the virus being known, the complete sequences of the proteins could now be determined. The hope then was that both proteins could be made in quantity by expression in E. coli. In the event, the expectation was fulfilled only for the core protein; the coat protein, whose coding sequence was undeniably present in the bacteria, obsti-nately failed to express-a source of frustration all too familiar to researchers to this day. But to compensate, the work-presented in a landmark paper (16) in Nature in 1979-included an additional eye-catching observation: the expressed core protein had been used to generate antibodies in rabbits, and those antibodies had recognized an antigen in the blood of human hepatitis B patients.
The virus released into the blood of infected people (or chimpanzees) is accompanied by several other kinds of particle. They include viral capsids-intact spherical heads of the virus, emptied of their DNA-and globular or filamentous aggregates of single proteins or fragments of proteins, and, at a later stage, also antibodies against them. One such protein fragment-the one designated HBcAg-had proved highly immunogenic, but it was expressed in E. coli in only low yield. Changes introduced in the DNA sequence led to a much higher expression level and to a product with intact immunogenicity. This became the basis of a commercially disseminated diagnostic kit, which proved highly efficient, not to say profitable for Biogen. However, Ken wanted treatment and prevention, not mere diagnosis. Now that he and Gilbert had defined the genome structure, a wide choice of possible antigenic targets presented themselves. Another antigen, HBsAg, appeared especially promising, but again produced a minimal yield in the E. coli plasmid system. This time, moreover, it resisted all attempts to find a solution by genetic manipulation. Ken therefore turned to a different expression system, which had more recently come into favour. He and his group modified the DNA to render it compatible with a yeast vector. Yeast strains affording optimal expression levels had been developed; yeast cells can be grown almost as easily as E. coli, and in greater bulk. The microbially produced HBsAg gave rise to antibodies when injected into chimpanzees. These antibodies protected the animals against infection by high doses of a virulent hepatitis strain (18) . This was a giant leap, and more revelations followed.
The observation (19) that immunity could be developed against the very reactive antigen, HBcAg, derived (as its designation implies) from the virus core, was unexpected, indeed counterintuitive. It implied that antibodies against an internal, therefore presumptively shielded, protein in the virus could give protection against the disease. This would have been an incentive to prepare antibodies against other hepatitis B proteins, such as the viral DNA polymerase (the enzyme responsible for DNA replication), a direction that was later followed. Ken and his colleagues preferred instead to explore the effects of single and multiple mutations in the HBsAg gene sequence. The object was to determine the extent to which the antigenic specificity could be altered, or more especially broadened to encompass two or more epitopes (separate antigenic elements in the molecule), and thus evade any suppression of immunogenicity through spontaneous mutation of the virus. This exacting work was performed with the uncompromising thoroughness that was so characteristic of Ken's style. The outcome was remarkably successful, and the strategy probably new to immunological practice. For a lucid survey of this and the foregoing work, see reviews by Ken and his co-workers (20, 22) .
Ken further enlarged the scope of this general approach by generating antibodies against fusion hybrids containing epitopes of both a coat and a core protein. This exposed a striking synergy between the two antigenic sites. Ken also struck out in yet another direction-the use of oligopeptide homologues of protein interaction sites as competitive inhibitors of virus assembly in the host cell (23)-but this line of inquiry was not taken beyond the exploratory stage. There were more studies aimed at maximizing the efficacy and specificity of the diagnostic and therapeutic materials. Ken maintained his interest in hepatitis B until the vaccine became commercially established, and also in the application of the techniques that he and others had developed to viral pathogens more generally (21). The hepatitis B vaccine, based on Ken's anti-coat protein antibody, received the blessing of the FDA in 1982, and was marketed that year by Biogen. It was the first genetically engineered vaccine. It later transpired that a group of virologists at the Pasteur Institute in Paris had been working along similar lines, and were close on the Edinburgh team's heels. Neither side was apparently aware that it was in a race for the patent rights, and of course the glory. But it had been, as Ken later observed (quoting the Duke of Wellington), 'a damned close-run thing'.
Despite the success of the endeavour to produce hepatitis B viral antigens in E. coli, the Biogen patent was the subject of an extensive legal dispute that inevitably occupied much of Ken's time and nervous energy. In 1992 Biogen began infringement proceedings against Medeva plc, which was proposing to market a hepatitis B vaccine made by recombinant DNA technology and produced in cultured mammalian cells. Medeva counterclaimed for revocation of the Biogen patent on the grounds of both obviousness and insufficiency of disclosure. The 1978 priority date of the patent was also challenged. The UK High Court held that the claims in the 1990 European patent were supported by matter disclosed in the 1978 priority document. The obviousness and insufficiency objections were dismissed, and the patent was adjudged valid and infringed. An appeal was granted, and the Court of Appeal ruled that the priority document did not support the claimed invention, that it was obvious at the earlier date and that the descriptions were insufficient to support the claims. A third reiteration in the House of Lords essentially supported the decision of the Court of Appeal, although on the basis of a different legal argument. Fortunately for Biogen, in July 1994 the European Patent Office's Technical Board of Appeal dismissed the opposition proceedings against the European Patent.
The hepatitis vaccine set Biogen on the path to commercial ascendancy. Sales now amount to more than US$1 billion per year, and more than one billion doses have so far been dispensed. The vaccine has saved an incalculable number of lives, among which should be included those of patients who survived the infection but would have contracted cancer, because it has been estimated that some 80% of liver cancer cases result from hepatitis B infections. In this sense the Biogen vaccine counts as an anti-cancer vaccine.
teaching and the embl interlude
In 1979 Ken and Noreen took what amounted to a three-year sabbatical at the European Molecular Biology Laboratory (EMBL) in Heidelberg. It was no rest cure: the Murrays did not reduce the pace of their research activity while exerting themselves to offer instruction and advice to members of the institution. They had made the move in response to an invitation from Sir John Kendrew FRS, the director of the parent European Molecular Biology Organization (EMBO), who paid tribute to the invigorating effect of their presence. But they exerted a wider influence by designing and teaching a laboratory course on genetic engineering, in association with several other experts whom they recruited. The beneficiaries were mainly young researchers from around Europe, and many were the tributes from those whose careers the course helped to launch. Ken took a deep interest in scientific education. He was, in his low-key style, a fluent and stimulating teacher. He set great store by the ability of a lecturer to communicate the allure of his subject. He reminisced on one occasion about the inspiration he had drawn as an undergraduate in Birmingham from an introductory lecture by the eminent saccharide chemist, Maurice Stacey. Stacey, he recalled, wrote the formula of glucose on the blackboard three times, each time differently and each time incorrectly, but it was the enthusiasm that shone through and engaged his listeners.
At the end of their stint in Heidelberg, Ken and Noreen returned to Edinburgh, Ken to occupy the newly founded Biogen Chair of Molecular Biology. He continued to work on vaccines and to supervise students. Much of the research outlined above was performed between that time and his retirement in 1998, although retirement did not put an end to his immersion in work. Science remained central to his life, and he was still to be found in his office daily until very shortly before his death.
Ken's science was marked, like his written and spoken communication, by an unfailing clarity and precision. Ken was meticulous in all things. Even his handwriting-he preferred a fountain pen-was small, flawless and elegant. He made clear to his students that worthwhile research demanded persistence and hard work, and he, like Noreen, led by example. Throughout their careers they worked with immense application. Long days at the bench, and seven-day weeks, were not unusual when demanding experiments dictated. Ken was a man of strong principles and convictions. In engaging with the commercial world as a founder of Biogen, he incurred a good deal of obloquy from academic colleagues. The very idea of a spin-off company, now such a commonplace, was then widely seen as a betrayal of trust, but Ken persisted and was vindicated. Biogen was a huge success, and the royalties accruing from sales of the hepatitis vaccine made Ken rich. But Ken had little interest in personal wealth, and apart from a pied-à-terre in London, and a few pictures to decorate the walls, he devoted the proceeds to good works. He donated a large proportion of the income-about half of his total charitable donations-to the University of Edinburgh, for example to fund improvements of the university library facilities. He also gave support to a programme for bringing science to local schoolchildren. But above all he founded and funded a charity, the Darwin Trust of Edinburgh, dedicated to education and research in the biological sciences and to promoting the careers of aspiring young scientists of high promise. Since its inception in 1983 the trust has flourished, having funded more than 350 PhD students and some 50 undergraduates, mainly but not exclusively in Edinburgh. It has also supported faculty and building projects at Edinburgh and elsewhere. It continues in this work today and it is hoped that it will survive in perpetuity as an extraordinary legacy.
Ken Murray was a much-loved and admired figure, unpretentious and self-effacing. He received many honours in the course of his illustrious career, including a knighthood conferred on him in 1993 (figure 6) and the Royal Society's Royal Medal in 2012 (figure 7). Many felt that Ken could justly have been awarded the Nobel Prize. According to his perceptive obituarist, Tam Dalyell (Dalyell 2013), no less an authority than Lord (George) Porter FRS, former President of the Royal Society, opined that had Ken been less reticent and 'more pushy', that apotheosis might have come to him. Ken had a legion of friends around the world. He and Noreen offered a warm welcome and generous hospitality to their many visitors in Edinburgh and London. In retirement they found more time to indulge their pleasure in music and theatre, and Ken read widely, but especially nineteenth-century and twentieth-century history. In his younger days he had been a keen hiker and rock-climber, and later in life he and Noreen still enjoyed long country walks, until he was smitten with rheumatoid arthritis, which severely impaired his mobility. Noreen died in 2011, leaving Ken's nephew, Keith, as his only close relative.
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